---
figid: PMC9652818__40164_2022_357_Fig1_HTML
figtitle: 'N6-methyladenosine (m6A) modifications in gynecologic cancers: mechanisms
  and therapeutic targeting'
organisms:
- Mus musculus
- Human papillomavirus
- Transposon gamma-delta
- Human papillomavirus type 16
- Drosophila melanogaster
- Homo sapiens
organisms_ner:
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
- Danio rerio
pmcid: PMC9652818
filename: 40164_2022_357_Fig1_HTML.jpg
figlink: /pmc/articles/PMC9652818/figure/Fig1/
number: F1
caption: In OC, m6A regulatory proteins contribute to tumorigenesis and metastasis
  by interacting with various RNAs. METTL3 and METTL14 stimulate the progression of
  OC by promoting the expression levels of FZD10, CSF-1, EIF3C, AXL, RHPN-AS1, miR-125-5p,
  and TROAP. HOXA10 forms a loop with ALKBH5 and jointly activates the JAK2/STAT3
  signaling pathway by mediating JAK2 m6A methylation and promoting the OC resistance
  to cisplatin. The activated NF-κB up-regulates ALKBH5 expression and increases m6A
  level and NANOG expression, contributing to ovarian carcinogenesis. FTO and ALKBH5
  stimulate/inhibit the progression of OC by affecting the expression levels of ATG5,
  ATG7, PDE1C, PDE4B, and FZD10.YTHDF1, YTHDF2 and IGF2BP1 stimulate/inhibit the progression
  of OC by affecting the expression of BMF, TRIM29, EIF3C, SRF, and UBA6. In addition,
  FBW7 and miR-145 inhibit the expression of YTHDF, leading to OC suppression
papertitle: 'Roles of N6-methyladenosine (m6A) modifications in gynecologic cancers:
  mechanisms and therapeutic targeting.'
reftext: Jiahua Chen, et al. Exp Hematol Oncol. 2022;11:98.
year: '2022'
doi: 10.1186/s40164-022-00357-z
journal_title: Experimental Hematology & Oncology
journal_nlm_ta: Exp Hematol Oncol
publisher_name: BioMed Central
keywords: N6-methyladenosine | Gynecologic cancer | Tumor microenvironment | Prognosis
  | Treatment
automl_pathway: 0.9039323
figid_alias: PMC9652818__F1
figtype: Figure
redirect_from: /figures/PMC9652818__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9652818__40164_2022_357_Fig1_HTML.html
  '@type': Dataset
  description: In OC, m6A regulatory proteins contribute to tumorigenesis and metastasis
    by interacting with various RNAs. METTL3 and METTL14 stimulate the progression
    of OC by promoting the expression levels of FZD10, CSF-1, EIF3C, AXL, RHPN-AS1,
    miR-125-5p, and TROAP. HOXA10 forms a loop with ALKBH5 and jointly activates the
    JAK2/STAT3 signaling pathway by mediating JAK2 m6A methylation and promoting the
    OC resistance to cisplatin. The activated NF-κB up-regulates ALKBH5 expression
    and increases m6A level and NANOG expression, contributing to ovarian carcinogenesis.
    FTO and ALKBH5 stimulate/inhibit the progression of OC by affecting the expression
    levels of ATG5, ATG7, PDE1C, PDE4B, and FZD10.YTHDF1, YTHDF2 and IGF2BP1 stimulate/inhibit
    the progression of OC by affecting the expression of BMF, TRIM29, EIF3C, SRF,
    and UBA6. In addition, FBW7 and miR-145 inhibit the expression of YTHDF, leading
    to OC suppression
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Eif3c
  - Axl
  - Csf1
  - Fzd10
  - Fzd2
  - Mettl3
  - Fto
  - Pde1c
  - Atg5
  - Troap
  - Mettl14
  - Alkbh5
  - Nanog
  - Jak2
  - Hoxa10
  - Nfkb1
  - Fbxw7
  - Ythdf2
  - Ythdf1
  - Igf2bp1
  - B4galnt2
  - Mir145a
  - Bmf
  - Trim29
  - Srf
  - Uba6
  - EIF3C
  - AXL
  - CSF1
  - FZD10
  - METTL3
  - FTO
  - PDE1C
  - PDE7A
  - PDE7B
  - ATG5
  - TROAP
  - METTL14
  - ALKBH5
  - NANOG
  - JAK2
  - HOXA10
  - NFKB1
  - FBXW7
  - YTHDF2
  - YTHDF1
  - IGF2BP1
  - MIR145
  - BMF
  - TRIM29
  - SRF
  - UBA6
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - eIF3c
  - Dif
  - dl
  - Rel
  - Imp
  - mal
  - bs
  - eif3c
  - axl
  - foxa2
  - fzd10
  - mettl3
  - fto
  - pde1cb
  - atg5
  - troap
  - mettl14
  - alkbh5
  - nanog
  - jak2b
  - hoxa10b
  - ythdf2
  - ythdf1
  - igf2bp1
  - mir145
  - srfa
  - uba6
  - NANOG
---
